Related references
Note: Only part of the references are listed.Risk of atypical femoral fracture during and after bisphosphonate use Full report of a nationwide study
Jorg Schilcher et al.
ACTA ORTHOPAEDICA (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Calcium Supplements Increase Risk of Myocardial Infarction
Mark J. Bolland et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effects of Calcium Supplementation on Verified Coronary Heart Disease Hospitalization and Death in Postmenopausal Women: A Collaborative Meta-Analysis of Randomized Controlled Trials
Joshua R. Lewis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Second Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial
Benjamin Z. Leder et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis
Ian R. Reid et al.
LANCET (2014)
Bazedoxifene/conjugated estrogens for managing the burden of estrogen deficiency symptoms
Sebastian Mirkin et al.
MATURITAS (2014)
Calcium risk-benefit updated-New WHI analyses
Ian R. Reid et al.
MATURITAS (2014)
Women's Health Initiative clinical trials: interaction of calcium and vitamin D with hormone therapy
John A. Robbins et al.
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY (2014)
Risk of Atypical Femoral Fracture during and after Bisphosphonate Use
Jorg Schilcher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers
U. C. Bang et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population
T. -C. Lin et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Skeletal and nonskeletal effects of vitamin D: is vitamin D a tonic for bone and other tissues?
I. R. Reid et al.
OSTEOPOROSIS INTERNATIONAL (2014)
A comparison of adverse event and fracture efficacy data for strontium ranelate in regulatory documents and the publication record
Mark J. Bolland et al.
BMJ OPEN (2014)
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study
Douglas C. Bauer et al.
JAMA INTERNAL MEDICINE (2014)
Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy
Maryam Sharifi et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2014)
Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis
Prashanth Peddi et al.
CANCER TREATMENT REVIEWS (2013)
Effect of calcium or vitamin D supplementation on vascular outcomes: A meta-analysis of randomized controlled trials
Pei-Juan Mao et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Osteoporosis drugs in real-world clinical practice: an analysis of persistence
Giovanni Iolascon et al.
AGING CLINICAL AND EXPERIMENTAL RESEARCH (2013)
Five years of anti-resorptive activity after a single dose of zoledronate - Results from a randomized double-blind placebo-controlled trial
Andrew Grey et al.
BONE (2012)
Adverse events from calcium supplementation: Relationship to errors in myocardial infarction self-reporting in randomized controlled trials of calcium supplementation
Joshua R. Lewis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Five Years of Continued Therapy in a Phase 2 Study
Bente Langdahl et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The US Postmarketing Surveillance Study of Adult Osteosarcoma and Teriparatide: Study Design and Findings From the First 7 Years
Elizabeth B. Andrews et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Incidence of Atypical Nontraumatic Diaphyseal Fractures of the Femur
Richard M. Dell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the Reduction in New Vertebral Fractures in Subjects with Primary Osteoporosis and High Fracture Risk
Toshitaka Nakamura et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Comparative Effectiveness of Drug Treatments to Prevent Fragility Fractures: A Systematic Review and Network Meta-Analysis
Mohammad Hassan Murad et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Strontium ranelate-induced DRESS syndrome
M. Le Merlouette et al.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2011)
Bisphosphonate-related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis
M. Manfredi et al.
INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2011)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effects of Intravenous Zoledronic Acid Plus Subcutaneous Teriparatide [rhPTH(1-34)] in Postmenopausal Osteoporosis
Felicia Cosman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Odanacatib in the Treatment of Postmenopausal Women With Low Bone Mineral Density: Three-Year Continued Therapy and Resolution of Effect
John A. Eisman et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Inhibition of Sclerostin by Monoclonal Antibody Enhances Bone Healing and Improves Bone Density and Strength of Nonfractured Bones
Michael S. Ominsky et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Jorg Schilcher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis
Mark J. Bolland et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25-dihydroxyvitamin D
David M. Slovik et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
The diagnosis of osteoporosis
John A. Kanis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Effects of Denosumab on Bone Histomorphometry: The FREEDOM and STAND Studies
Ian R. Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Characterization of and Risk Factors for the Acute-Phase Response after Zoledronic Acid
I. R. Reid et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
Mark J. Bolland et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe
B. Abrahamsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe
B. Abrahamsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women
Robert Lindsay et al.
FERTILITY AND STERILITY (2009)
Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Third International Workshop
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies
Leon A. Assael
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2009)
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Steven R. Cummings et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K
Jacques Yves Gauthier et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
Paul D. Miller et al.
BONE (2008)
Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis
Steven Boonen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Bisphosphonate use and the risk of adverse jaw outcomes
Vassiliki M. Cartsos et al.
JOURNAL OF THE AMERICAN DENTAL ASSOCIATION (2008)
Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks
N. D. Nguyen et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA
B. Dawson-Hughes et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
FRAX™ and the assessment of fracture probability in men and women from the UK
J. A. Kanis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker
M. Pazianas et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
Jacques E. Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis - A randomized trial
Susan L. Greenspan et al.
ANNALS OF INTERNAL MEDICINE (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Calcium plus vitamin D supplementation and the risk of fractures
RD Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass
MR McClung et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters
M Arlot et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
JY Reginster et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women
IR Reid et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial
GL Anderson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Vitamin D and calcium supplementation prevents osteoporotic fractures in elderly community dwelling residents: A pragmatic population-based 3-year intervention study
ER Larsen et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis
PJ Meunier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis
R Lindsay et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis
DM Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Pharmacovigilance study of alendronate in England
PN Biswas et al.
OSTEOPOROSIS INTERNATIONAL (2003)
The components of excess mortality after hip fracture
JA Kanis et al.
BONE (2003)
Risks and benefits of estrogen plus progestin in healthy postmenopausal women - Principal results from the Women's Health Initiative randomized controlled trial
JE Rossouw et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
RM Neer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effect of risedronate on the risk of hip fracture in elderly women
MR McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Prevalence of osteoporosis in Australian women - Geelong Osteoporosis study
MJ Henry et al.
JOURNAL OF CLINICAL DENSITOMETRY (2000)
Share Paper
